| Literature DB >> 8635390 |
Abstract
Lung cancer, the most prevalent cancer in the western world, is predominantly caused by smoking and thus perceived as a "self-inflicted" disease. Nevertheless, only 20% of smokers develop lung cancer. This review examines the concept of high-risk populations and screening. It looks at developments in the molecular epidemiology of the disease that shed new light on genetic changes that may predispose individuals to malignancy. Improvements in existing drug therapy are discussed as well as important new therapeutic developments, including antigrowth factors (antagonists G and D), antimetastatic agents (matrix metalloproteinase inhibitors), and natural products, arising from a greater understanding of signal transduction pathways and the process of cell metastasis.Entities:
Mesh:
Substances:
Year: 1996 PMID: 8635390 DOI: 10.1378/chest.109.5_supplement.125s
Source DB: PubMed Journal: Chest ISSN: 0012-3692 Impact factor: 9.410